Biggest stock movers Friday: AVGO, RH, and more

Stock futures inched higher in premarket trading on Friday, following a volatile week filled with hotter-than-expected economic data releases. Market participants are now shifting their focus to next week’s U.S. Federal Reserve meeting.

Here are some of Friday’s biggest stock movers:

Biggest stock gainers

• Broadcom (AVGO) shares climbed 14% after reporting FQ4 results, showcasing a 44% Y/Y increase in full-year revenue to a record $51.6B. This growth was fueled by $21.5B in infrastructure software revenue, bolstered by VMware integration, and $30.1B in semiconductor revenue, which included $12.2B from AI-related sales—a 220% Y/Y surge. The company projected revenue of $14.6B for the ongoing quarter, aligning with market expectations. Broadcom also announced an 11% increase in its quarterly dividend to $0.59 per share for fiscal 2025, targeting a record annual dividend of $2.36 per share, marking its 14th consecutive annual increase since 2011.
• RH (RH) shares jumped over 17% following its FQ3 report, highlighting a 13% rise in demand despite operating in one of the toughest housing markets in three decades. Revenue grew 8.1% Y/Y to $811.7M, aligning with expectations. The company attributed its growth to the success of the RH brand, with November demand surging 24% after launching the RH Modern Sourcebook and December showing continued momentum with a 30% increase in month-to-date demand. RH stated its focus on unmatched design and quality is disrupting multiple markets, positioning it for significant market share gains. For FQ4, RH projects revenue growth of 18%-20% vs. the consensus growth of 7% Y/Y and an adjusted operating margin between 12.2% and 13.2%.

Biggest stock losers

• Shares of Repare Therapeutics (RPTX) plunged over 38% after the company announced Phase 1 results for its combination therapy of lunresertib and camonsertib targeting endometrial and ovarian cancer. The therapy demonstrated a 25.9% overall response rate in endometrial cancer and 37.5% in platinum-resistant ovarian cancer, with anemia (Grade 3, 26.9%) reported as the most common adverse event. Repare plans to launch a Phase 3 registrational study for endometrial cancer in the second half of 2025.
• Shares of Bitcoin miner CleanSpark (CLSK) declined 3% after announcing plans to offer $550M in convertible senior notes due 2030 in a private offering to institutional buyers. The company also intends to grant an option to the initial purchasers to buy up to an additional $100M in notes within 13 days. Net proceeds will be used for capped call transactions, share repurchases, repayment of debt with Coinbase, capital expenditures, acquisitions, and general corporate purposes. The convertible notes are set to mature on June 15, 2030.